SURF1 Deficiency: Expanding on Disease Phenotype and Assessing Disease Burden by Describing Clinical and Biochemical Phenotype
American Journal of Medical Genetics Part A · 2025
DOI: 10.1002/ajmg.a.63947 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Medical Genetics Part A, 2025. Verfasst von Saima Kayani und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, UTSW Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Leigh Disease, Membrane Proteins, Mitochondrial Proteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Leigh syndrome, a severe neurological disorder is commonly caused by homozygous or bi‐allelic pathogenic variants in the SURF1 gene. SURF1 deficiency leads to dysfunction of Cytochrome C Oxidase (COX) activity, which is crucial for mitochondrial oxidative phosphorylation. Understanding COX activity's correlation with disease severity is essential for developing SURF1 Leigh Syndrome biomarkers. This study assesses the disease burden in SURF1 Leigh Syndrome and evaluates COX activity as a treatment biomarker. We reviewed records and questionnaires from 17 individuals, classifying them into phenotypic and genotypic groups. We compared COX activity assays in patient fibroblasts to age‐matched controls, clinical data, and neuroimaging findings. Patient COX activity was at most 50% of controls, averaging 32% ( p < 0.001). Common clinical features included brainstem abnormalities (93.3%), motor regression (92.3%), bi‐allelic heterozygous SURF1 variants (88.2%), and delayed growth/development (35.7%). Homozygous and heterozygous nonsense/frameshift variants showed more severe phenotypes ( p = 0.008) and more MRI abnormalities ( p = 0.005). Significant COX activity reduction is linked to SURF1 Leigh Syndrome, with genotype influencing disease severity. Clinical and neuroimaging correlations show potential for prognostic indicators. This study lays the groundwork for future research and clinical application of COX activity as a SURF1 Leigh Syndrome biomarker.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, UTSW Medical Center, Dallas, Texas, USA.
- Children's Health, Dallas, Texas, USA.
- Perot Foundation Neuroscience Translational Research Center, Peter O'Donnell Jr. Brain Institute, UT Southwestern Medical Center, Dallas, Texas, USA.
- Cure Mito Foundation, USA.
ORCID-Profile: Hamza Dahshi
Zitieren
APA
Kayani, S., Daescu, V., Dahshi, H., Messahel, S., Woleban, K., Minassian, B. A., Ling, Q., & Gray, S. J. (2025). SURF1 Deficiency: Expanding on Disease Phenotype and Assessing Disease Burden by Describing Clinical and Biochemical Phenotype. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.63947
Vancouver
Kayani S, Daescu V, Dahshi H, Messahel S, Woleban K, Minassian BA, et al. SURF1 Deficiency: Expanding on Disease Phenotype and Assessing Disease Burden by Describing Clinical and Biochemical Phenotype. American Journal of Medical Genetics Part A. 2025. doi:10.1002/ajmg.a.63947
BibTeX
@article{Kayani2025,
author = {Kayani, Saima and Daescu, Victor and Dahshi, Hamza and Messahel, Souad and Woleban, Kasey and Minassian, Berge A and Ling, Qinglan and Gray, Steven J},
title = {SURF1 Deficiency: Expanding on Disease Phenotype and Assessing Disease Burden by Describing Clinical and Biochemical Phenotype},
journal = {American Journal of Medical Genetics Part A},
year = {2025},
doi = {10.1002/ajmg.a.63947}
}
EUVIMED